Introduction {#s1}
============

The active form of vitamin D~3~, 1,25-dihydroxyvitamin D~3~ **\[**1α,25(OH)~2~D~3~; **1\]** (Table [1](#T1){ref-type="table"}), is mostly known for its effects on bone, calcium, and phosphate homeostasis. Next to these classical effects, 1,25(OH)~2~D~3~ also exerts so-called non-classical effects on various tissues which express the vitamin D receptor (VDR) as well as the enzymes that are responsible for activating the hydroxylations of vitamin D~3~, which is essential for the formation of 1,25(OH)~2~D~3~. Thus, most tissues have the ability to convert vitamin D~3~ into its active form, 1,25(OH)~2~D~3~, which in turn will bind the VDR in order to positively or negatively influence target genes via binding of the 1,25(OH)~2~D~3~/VDR complex to vitamin D receptor elements (VDRE). Non-classical properties of 1,25(OH)~2~D~3~ include prodifferentiating and antiproliferative effects on normal and cancer cells (Colston et al., [@B14]; Jensen et al., [@B44]) as well as immunomodulatory effects. However, in order to obtain these non-classical effects, 1,25(OH)~2~D~3~ doses of the nanomolar range are necessary, while physiological 1,25(OH)~2~D~3~ serum concentrations are in the picomolar range. Since supraphysiological doses of 1,25(OH)~2~D~3~ result in hypercalcemia, 1,25(OH)~2~D~3~ analogs were developed to minimize the calcemic side effects while preserving or augmenting the beneficial effects of 1,25(OH)~2~D~3~. Both industry and academic institutions have synthesized a vast amount of vitamin D analogs. Some of these analogs have tissue-specific effects with low calcemic side effects and can be given at higher doses compared to the mother compound.

###### 

**Overview of vitamin D analogs**.

  **Identification number**   **Name**                                                                 **Structure**
  --------------------------- ------------------------------------------------------------------------ ---------------
  **\[1\]**                   1α,25(OH)~2~D~3~                                                         
  **\[2\]**                   Paricalcitol (19-nor-1α,25(OH)~2~D~2~)                                   
  **\[3\]**                   Doxercalciferol (1α(OH)D~2~)                                             
  **\[4\]**                   Falecalcitriol (26,27 F6-1α,25(OH)~2~D~3~)                               
  **\[5\]**                   Maxacalcitol (22oxa-1α,25(OH)~2~D~3~)                                    
  **\[6\]**                   Tacalcitol (1α,24(R)(OH)~2~D~3~)                                         
  **\[7\]**                   Calcipotriol (22-ene-26,27-dehydro-1α,25(OH)~2~D~3~)                     
  **\[8\]**                   Alfacalcidol (1α(OH)D~3~)                                                
  **\[9\]**                   Eldecalcidol (2β-(3-hydroxypropoxy)-1α,25(OH)~2~D~3~)                    
  **\[10\]**                  Seocalcitol (22,24-diene-24,26,27-trishomo-1α,25(OH)~2~D~3~**)**         
  **\[11\]**                  20-epi-1α,25(OH)~2~D~3~                                                  
  **\[12\]**                  Lexicalcitol (20-epi-22-oxa-24,26,27-trishomo-1α,25(OH)~2~D~3~)          
  **\[13\]**                  CD578 (17-methyl-19-nor-21-nor-23-yne-26,27-F6-1α,25(OH)~2~D~3~)         
  **\[14\]**                  Inecalcitol (19-nor-14-epi-23-yne-1α,25(OH)~2~D~3~)                      
  **\[15\]**                  TX527 (19-nor-14,20-bisepi-23-yne-1α,25(OH)~2~D~3~)                      
  **\[16\]**                  2MD (2-methylene-19-nor-(20S)-1α,25(OH)~2~D~3~)                          
  **\[17\]**                  WY1112 (Seco-C-9,11-bisnor-17-methyl-20-epi-26,27-F6-1α,25(OH)~2~D~3~)   
  **\[18\]**                  PRI-2205 ((5E,7E)-22-ene-26,27-dehydro-1α,25(OH)~2~D~3~)                 
  **\[19\]**                  ILX23-7553 (16-ene-23-yne-1α,25(OH)~2~D~3~)                              

Clinically approved vitamin D analogs
=====================================

Given the huge amount of vitamin D analogs that have been synthesized during the years, it is nearly impossible to give an overview of them all. In the first part we will discuss vitamin D analogs that are clinically approved (Table [2](#T2){ref-type="table"}). For several conditions such as secondary hyperparathyroidism, psoriasis and osteoporosis, vitamin D analogs are frequently used as a treatment option. Paricalcitol **\[2\]** and doxercalciferol **\[3\]** are vitamin D~2~ analogs approved for therapeutic use of secondary hyperparathyroidism. In Japan falecalcitriol **\[4\]** and maxacalcitol **\[5\]** are also used to treat this disease. Secondary hyperparathyroidism is characterized by elevated parathyroid hormone (PTH) levels in response to hypocalcemia and is often caused by chronic kidney disease. Above-mentioned vitamin D analogs suppress PTH, as does 1,25(OH)~2~D~3~, but without inducing severe hypercalcemia. Clinical studies with chronic kidney disease patients show that different analogs induce a stronger PTH suppression compared to placebo treatment (Hamdy et al., [@B34]; Coburn et al., [@B13]; Coyne et al., [@B15]). Also, end-stage renal disease patients treated with these analogs often have a better survival (Teng et al., [@B93]; Tentori et al., [@B94]; Shinaberger et al., [@B90]). However, few studies with chronic kidney disease and end-stage renal disease patients directly compare the effects of 1,25(OH)~2~D~3~ with its analogs.

###### 

**Overview of clinically approved vitamin D analogs**.

  **Name**                                                 **Structure**   **Indication**                                             **Brand name**
  -------------------------------------------------------- --------------- ---------------------------------------------------------- --------------------------------------------------------------------
  Tacalcitol (1α,24(R)(OH)~2~D~3~)                                         Psoriasis                                                  Curatoderm® (Almirall Hermal), Bonalfa® (ISDIN, Teijin Pharma),...
  Paricalcitol (19-nor-1α,25(OH)~2~D~2~)                                   Secondary hyperparathyroidism                              Zemplar® (Abbott)
  Doxercalciferol (1α(OH)D~2~)                                             Secondary hyperparathyroidism                              Hectorol® (Genzyme corp)
  Falecalcitriol (26,27 F6-1α,25(OH)~2~D~3~)                               Secondary hyperparathyroidism (Japan only)                 Fulstan® (Dainippon Sumitomo) and Hornel® (Taisho Yakuhin)
  Maxacalcitol (22oxa-1α,25(OH)~2~D~3~)                                    Secondary hyperparathyroidism and psoriasis (Japan only)   Oxarol® (Chugai Pharmaceutical)
  Calcipotriol (22-ene-26,27-dehydro-1α,25(OH)~2~D~3~)                     Psoriasis                                                  Daivonex®, Dovonex® (LEO Pharma), Sorilux® (Stiefel)
  Eldecalcitol (2β-(3-hydroxypropoxy)- 1α,25(OH)~2~D~3~)                   Osteoporosis (Japan only)                                  Edirol® (Chugai Pharmaceutical)

Psoriasis, a hyperproliferative condition of the skin, is also treated with vitamin D analogs. Tacalcitol **\[6\]**, calcipotriol **\[7\]** and the recently approved maxacalcitol **\[5\]** are used either as monotherapy or in combination with topical steroids such as betamethasone dipropionate to treat psoriasis. The analogs exert prodifferentiating and antiproliferative effects on keratinocytes and also possess important anti-inflammatory properties. Furthermore, alfacalcidol (**\[**1α(OH)D~3~; **8\]**, actually a pre-metabolite of 1,25(OH)~2~D~3~) and eldecalcitol (ED-71) **\[9\]** are used in Japan in the treatment of osteoporosis. The recently approved eldecalcitol **\[9\]** is more effective than 1,25(OH)~2~D~3~ and alfacalcidol **\[8\]** in increasing bone mineral density and mechanical strength in ovariectomized rats (Uchiyama et al., [@B96]). Various studies in mouse models as well as in patients show that treatment with eldecalcitol **\[9\]** leads to higher lumbar and hip bone mineral density and a lower incidence of new vertebral fractures (Ito et al., [@B41]; Matsumoto et al., [@B64]; Harada et al., [@B37]; Hagino et al., [@B33]), making eldecalcitol **\[9\]** a very promising new analog for the treatment of osteoporosis.

Genome- and transcriptome-wide effects of vitamin D analogs
===========================================================

The exact mechanism of action of vitamin D analogs still has to be deciphered. The reason why specific analogs have superagonistic actions on specific tissues remains unknown, however several studies have tried to elucidate the mechanisms behind these tissue-specific effects. The catabolism of vitamin D analogs is one of the mechanisms that have an effect on their potency. Modifications of the side chain of 1,25(OH)~2~D~3~ are known to slow down its catabolism by CYP24A1 (Jones, [@B45]). Seocalcitol (EB1089) **\[10\]** and 20-epi-1,25(OH)~2~D~3~ **\[11\]** are degraded slower compared to 1,25(OH)~2~D~3~ leading to a longer exposure of these analogs to the tissues (Hansen and Maenpaa, [@B35]; Kissmeyer et al., [@B48]; Shankar et al., [@B89]; Zella et al., [@B109]). The metabolites formed after catabolism of lexicalcitol **\[12\]** are more active than the ones formed after 1,25(OH)~2~D~3~ is catabolized (Dilworth et al., [@B18]) and this analog is also more effective in slowing down the degradation rate of the VDR (van den Bemd et al., [@B98]). Moreover, since some cell types prefer specific catabolism pathways and enzymes above others, the degradation process may also contribute to the tissue-specific activity of vitamin D analogs. The affinity for the vitamin D binding protein (DBP) also plays a role in the activity of vitamin D analogs. Maxacalcitol **\[5\]** for example has a 500 times lower affinity for DBP and is thus cleared faster from the circulation than 1,25(OH)~2~D~3~ (Okano et al., [@B74]). This analog has a short effect on bone and intestine, tissues responsible for calcium homeostasis, and a longer effect on PTH levels, making this analog ideal for the treatment of secondary hyperparathyroidism. However, it is still unknown why the duration of the effects is different in these tissues. Eldecalcitol **\[9\]** on the other hand has a higher DBP affinity compared to the mother compound, leading to longer sustained plasma levels and is thus more suitable for the treatment of osteoporosis (Okano et al., [@B75]).

Another mechanism that contributes to the superagonistic effects of vitamin D analogs is their interaction with the VDR, co-activators and VDREs. 20-epi-1,25(OH)~2~D~3~, a C-20 epimer of 1,25(OH)~2~D~3~ **\[11\]**, promotes heterodimerization between VDR and retinoid X receptor (RXR) (Liu et al., [@B58]). 20-epi-1,25(OH)~2~D~3~ **\[11\]** and other analogs like maxacalcitol **\[5\]**, CD578 **\[13\]**, inecalcitol **\[14\]**, and TX527 **\[15\]** require lower concentrations to recruit specific coactivators to the VDR/RXR/VDRE complex (Liu et al., [@B59]; Eelen et al., [@B22], [@B21]; Schwinn and DeLuca, [@B86]). Approximately 10- fold lower doses of inecalcitol **\[14\]** and TX527 **\[15\]** are needed, compared to 1,25(OH)~2~D~3~, to acquire the same amount of co-activator interactions (Eelen et al., [@B22]). Vitamin D analogs might also be able to induce tissue-specific effects by favoring binding to specific *VDRE* motifs in target gene promoters. Analogs with a 20-methyl group as well as seocalcitol **\[10\]** bound to a VDR/RXR complex preferably interact with the IP9 type of VDRE (Danielsson et al., [@B17]; Quack and Carlberg, [@B81]).

On the genome level, studies using chromatin immunoprecipitation (ChIP) and micro-array techniques have investigated 1,25(OH)~2~D~3~-regulated genes in different cell lines. One ChIP study compared the binding sites of the VDR in intestinal tissue after 1,25(OH)~2~D~3~ or 20-epi-1,25(OH)~2~D~3~ **\[11\]** treatment. This study shows that both 1,25(OH)~2~D~3~ and 20-epi-1,25(OH)~2~D~3~ **\[11\]** induce VDR binding to *CYP24A1* and *TRPV6* loci in the intestine, but the analog elicits a prolonged VDR binding to these genes leading to its superagonistic characteristics such as hypercalcemia *in vivo* (Zella et al., [@B109]). Other ChIP studies have tried to investigate the molecular mechanisms of some analogs in different tissues. In osteoblast cell models 2MD **\[16\]** bound to the VDR is able to bind VDREs at lower concentrations compared to 1,25(OH)~2~D~3~ (Yamamoto et al., [@B107]). Seocalcitol **\[10\]**, on the other hand, mediates the dissociation of Williams syndrome transcription factor of the aromatase promoter leading to inhibition of aromatase expression and activity in breast cancer cells which is one of the main therapeutic strategies in breast cancer patients (Lundqvist et al., [@B61]). In a recent paper binding sites of VDR and mothers against decapentaplegic homolog 3 (SMAD3) were investigated in hepatic stellar cells. These transforming growth factor β1 (TGFβ1)-activated cells play an important role in liver fibrosis. In this study it is shown that VDR and SMAD3 can at least transiently co-occupy the same genomic sites and function as enhancers of pro-fibrotic gene expression. However, when calcipotriol **\[7\]** is added, the TGFβ1-induced recruitment of SMAD3 is compromised and binding of VDR to these genomic sites is enhanced 10-fold meaning that liganded VDR antagonizes SMAD residency on chromatin and thereby suppresses pro-fibrotic gene expression (Ding et al., [@B19]). This genomic feedback circuit is a previously unknown mechanism of calcipotriol **\[7\]**.

Micro-array studies in various cancer cell lines such as leukemia, prostate, breast, colorectal, and ovarian cancer show that a variety of gene clusters are influenced by 1,25(OH)~2~D~3~ and its analogs (reviewed in Kriebitzsch et al., [@B49]). Cell growth, apoptosis, cellular adhesion and extracellular matrix composition, oxidative stress, immune function, intra- and intercellular signaling and steroid/lipid metabolism are frequently modulated processes in cells by 1,25(OH)~2~D~3~ and its analogs. However, when different cell lines are compared, few 1,25(OH)~2~D~3~/analog-regulated genes overlap, which suggests that 1,25(OH)~2~D~3~ and its analogs behave in a cell type- and tissue-specific way. Also studies using human T-cells (Baeke et al., [@B7]), rat ventricular heart tissue (Bae et al., [@B6]), and bone marrow-derived mouse dendritic cells (Griffin et al., [@B30]) have researched the impact of 1,25(OH)~2~D~3~ analogs on gene expression. In these studies genes important for cell growth, cell death and cell signaling are regulated, but also a large set of genes implicated in the migration of T-cells and dendritic cells are influenced. TX527 **\[15\]** imprints human T-cells with a migratory signature and targets them to sites of inflammation (Baeke et al., [@B7]). Paricalcitol **\[2\]** treatment of rats with cardiac hypertrophy prevents the progression of cardiac hypertrophy and the development into chronic heart failure. The genomic changes associated with cardiac hypertrophy in the ventricular heart tissue of these rats are, in part, reversed by paricalcitol **\[2\]** administration (Bae et al., [@B6]). Furthermore, other studies investigated if 1,25(OH)~2~D~3~ analogs are able to bind and regulate different genes compared to 1,25(OH)~2~D~3~. All conducted studies conclude that 1,25(OH)~2~D~3~ and its analogs induce or repress the same set of genes. Seocalcitol **\[10\]** induces a less malignant phenotype in SCC25 squamous cell carcinoma cells and modulates expression of genes important in cell cycle progression, cell adhesion, extracellular matrix composition, intra- and intercellular signaling, G-protein coupled function, redox balance, and steroid metabolism. In these cells, seocalcitol **\[10\]** regulates the same genes compared to 1,25(OH)~2~D~3~, however gene regulation by 1,25(OH)~2~D~3~ is more transient (Lin et al., [@B54]). Also WY1112, a seco-9,11-*bis*nor-17-methyl analog lacking the C-ring and with a 21-epi side chain which is fluorinated on C26 and C27 **\[17\]**, was investigated in MCF-7 breast cancer cells. Despite the 400-fold stronger antiproliferative capacity of WY1112 **\[17\]**, the same genes are upregulated after 1,25(OH)~2~D~3~ or WY1112 **\[17\]** treatment. However, the induction ability is much higher for the analog (Vanoirbeek et al., [@B100]). When treating human coronary artery smooth muscle cells with equal amounts of 1,25(OH)~2~D~3~ or paricalcitol **\[2\]** the same genes are regulated (Wu-Wong et al., [@B106]; Shalhoub et al., [@B88]). In conclusion, differences in action and capacity of vitamin D analogs are more due to their specific sensitivities to metabolism and their specific interaction with the VDR, co-activators and VDREs than from different gene regulations. However, to our knowledge no studies have yet looked into the potential differences elicited by analogs compared to 1,25(OH)~2~D~3~ in the fields of proteomics and epigenetics, which could help to understand the molecular mechanism of 1,25(OH)~2~D~3~ and its analogs on different cell and tissue types.

Effects of vitamin D analogs in cancer
======================================

The use of 1,25(OH)~2~D~3~ for the treatment of cancer gained interest since many tissues express vitamin D metabolizing enzymes as well as the VDR and because 1,25(OH)~2~D~3~ has potent antiproliferative and prodifferentiating effects on normal and malignant cell lines. Several analogs evaluated *in vitro* show stronger antiproliferative and prodifferentiating effects compared to the mother compound in different cancer cell lines. These compounds are further evaluated in rodent models to assess their anti-cancer activity and safety *in vivo*. All *in vivo* studies using rodent cancer models that were published between 2007 and 2013 are summarized in Table [3](#T3){ref-type="table"}. For studies preceding 2007, the reader is referred to other reviews (Eelen et al., [@B20]). In most studies the growth of the tumor is inhibited without inducing severe hypercalcemia when appropriate doses of vitamin D analogs are used (Abe et al., [@B1]; Kawa et al., [@B47], [@B46]; Akhter et al., [@B2], Blutt et al., [@B10]; Prudencio et al., [@B80]; Grostern et al., [@B31]; Flanagan et al., [@B26]; Albert et al., [@B3]; Wietrzyk et al., [@B105]; Zhang et al., [@B110]; Fichera et al., [@B25]; van Ginkel et al., [@B99]; Ghous et al., [@B28]; Lee et al., [@B52]; Schwartz et al., [@B84]; Gonzalez-Pardo et al., [@B29]; Seubwai et al., [@B87]; Berkovich et al., [@B8]; Chiang et al., [@B12]). However, in some models the analog dose that is effective in inhibiting tumor growth also causes hypercalcemia and lower survival of the treated animals (Albert et al., [@B4]). Not only tumor proliferation is modulated by vitamin D analogs, also apoptosis, angiogenesis, migration of tumor cells, etc. are affected by some analogs. In xenograft studies where apoptosis in the tumor was investigated after vitamin D analog treatment, apoptosis or the necrotic field in the tumor is augmented (James et al., [@B43]; VanWeelden et al., [@B101]; Hara et al., [@B36]; Vegesna et al., [@B102]; Lambert et al., [@B50]; Park et al., [@B76]). Inecalcitol (Hybrigenics, France) **\[14\]** treatment of mice with squamous cell carcinoma xenografts increases apoptosis in the tumors and this increase is higher for the analog compared to 1,25(OH)~2~D~3~, while the capacity of the analog to inhibit proliferation is equal compared to the mother compound (Ma et al., [@B62]). Most studies agree that vitamin D analogs also have an effect on tumor metastasis. Seocalcitol **\[10\]** reverses the growth-stimulatory effects of parathyroid hormone-related protein (PTHrP), which plays a major role in prostate cancer progression and metastasis, in a xenograft mouse model of prostate cancer. The same study shows that seocalcitol **\[10\]** also inhibits migration and invasion of these prostate cancer cells *in vitro* (Bhatia et al., [@B9]). This analog also reduces the number and surface area of bone metastasis originating from intracardially injected breast cancer cells (El Abdaimi et al., [@B23]). Vitamin D analogs are thus able to reduce the number and growth of metastasis originating from various types of cancer cells (Sato et al., [@B83]; Lokeshwar et al., [@B60]; Nakagawa et al., [@B68]; Park et al., [@B76]). However, in a study using mice with chemically induced breast cancer, the invasion capacity of the tumor after seocalcitol **\[10\]** treatment is not affected (Liska et al., [@B55]). The effect of vitamin D analogs on angiogenesis has also been studied *in vivo*, but here the results are more conflicting. Some studies show no effect of vitamin D analogs on angiogenesis (Oades et al., [@B69]; Valrance et al., [@B97]), while others find decreased angiogenesis of xenograft tumors. Intraperitoneal injections of inecalcitol **\[14\]** decrease the vascularity of xenografted prostate cancer cells (Okamoto et al., [@B72]) and oral treatment of colorectal tumors in rats with alfacalcidol **\[8\]** also inhibits tumor angiogenesis (Iseki et al., [@B40]). All *in vivo* studies conclude that vitamin D analogs inhibit tumor growth but vitamin D and its analogs often do not influence tumor number. Seocalcitol **\[10\]** was given as chemoprevention in a transgenic mouse model for androgen-independent prostate cancer. Tumor growth is inhibited, however, there is no prevention in the development of tumors (Perez-Stable et al., [@B77]).

###### 

***In vivo* studies in rodent cancer models treated with vitamin D analogs (intraperitoneal i.p.; subcutaneous s.c.) published between 2007 and 2013**.

  **Cancer type**                                                                                                                                                          **Dosage vitamin D analog**                                                                                                     **Duration of treatment**   **Outcome**                                                                                                       **References**
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------- --------------------------- ----------------------------------------------------------------------------------------------------------------- -------------------------------
  **Seocalcitol (22,24-diene-24,26,27-trishomo-1 α,25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                                              
  Chemically-induced breast cancer                                                                                                                                         7 μg/kg/week                                                                                                                    Approximately 80 days       Decreased tumor burden and volume                                                                                 Liska et al., [@B55]
  Chemically-induced breast cancer                                                                                                                                         Oral, 7 μg/kg/week                                                                                                              116 or 156 days             Prolonged latency of mammary gland tumors                                                                         Macejova et al., [@B63]
  Prostate cancer xenograft                                                                                                                                                i.p., 0.5 μg/kg every other day                                                                                                 45 days                     Reversal of growth stimulatory effects of PTHrP                                                                   Bhatia et al., [@B9]
  Hepatocellular carcinoma xenograft                                                                                                                                       Oral and i.p., 0.02/0.1/0.5 μg/kg/d                                                                                             Approximately 21 days       Inhibition of tumor growth                                                                                        Ghous et al., [@B28]
  Inoculation with mice breast cancer cells                                                                                                                                i.p., 20 ng 3×/week                                                                                                             6 weeks                     Inhibition of tumor growth, no inhibition of tumor angiogenesis                                                   Valrance et al., [@B97]
  **HY-11 (2-amino-3-deoxy-19-nor-22-ene-26-dihomo-27-dihomo-25(OH)D~3~**)                                                                                                                                                                                                                                                                                                                                                                               
  Inoculation with mice leukemia cells                                                                                                                                     i.p., 10^−5^ M/d                                                                                                                26 days                     50% increase in survival                                                                                          Yoon et al., [@B108]
  **Tacalcitol (1 α,24(R)(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                                                                          
  Inoculation with mice colorectal cancer cells                                                                                                                            Different concentrations s.c. (3 or 5×/week) or oral (3×/week) in combination with different concentrations of 5-fluorouracil   Variable duration           1 μg/kg/d optimal dose + prolongation of life span of mice (synergistic effect when combined with chemotherapy)   Milczarek et al., [@B65]
  Inoculation with mice or human colorectal cancer cells                                                                                                                   s.c., Different concentrations in combination with different concentraties of irinotecan or oxaliplatin                         Variable duration           Under certain experimental conditions vitamin D analogs and chemotherapy can work synergistically                 Milczarek et al., [@B66]
  **Inecalcitol (19-nor-14-epi-23-yne-1 α,25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                                                       
  Squamous cell carcinoma xenograft                                                                                                                                        i.p., 80/160/320 μg/mouse/d                                                                                                     3 days                      Inhibition of tumor growth, increased apoptosis, decreased proliferation                                          Ma et al., [@B62]
  Prostate cancer xenograft                                                                                                                                                i.p., 1300 μg/kg 3×/week                                                                                                        42 days                     Delay of tumor growth, 50% decrease in tumor weight and decreased tumor vascularity                               Okamoto et al., [@B72]
  **TX527** (**19-nor-14,20-bisepi-23-yne-1 α,25(OH)**~2~**D**~3~****)                                                                                                                                                                                                                                                                                                                                                                                   
  Kaposi sarcoma xenograft                                                                                                                                                 i.p., 10 μg/kg/d                                                                                                                4 days                      Decreased tumor progression                                                                                       Gonzalez-Pardo et al., [@B29]
  **Paricalcitol (19-nor-1 α,25(OH)**~2~**D**~2~**)**                                                                                                                                                                                                                                                                                                                                                                                                    
  Gastric cancer xenograft                                                                                                                                                 s.c., 100 ng/d 3×/week                                                                                                          4 weeks                     Lower tumor volume, reduced growth of intraperitoneal metastasis                                                  Park et al., [@B76]
  Pancreatic cancer xenograft                                                                                                                                              s.c., 2.5 μg/kg 3×/week                                                                                                         Variable duration           Inhibition of tumor growth                                                                                        Schwartz et al., [@B84]
  **Doxercalciferol (1 α (OH)D~2~**)                                                                                                                                                                                                                                                                                                                                                                                                                     
  Neuroblastoma xenograft                                                                                                                                                  Oral, 0.15/0.3 μg/d                                                                                                             5 weeks                     Lower tumor volume                                                                                                van Ginkel et al., [@B99]
  **Maxacalcitol (22oxa-1 α,25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                                                                     
  Cholangiocarcinoma xenograft                                                                                                                                             i.p., 15 μg/kg/d                                                                                                                17 days                     Inhibition of tumor growth                                                                                        Seubwai et al., [@B87]
  **Calcipotriol (22-ene-26,27-dehydro-1 α,25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                                                      
  UV-induced non-melanoma skin cancer                                                                                                                                      Topical application in combination with diclofenac and difluoromethylornithine                                                  17 weeks                    Decrease in number and area of tumors when combined with diclofenac                                               Pommergaard et al., [@B79]
  **BGP-13 (1R, 3S, 5Z)-5-((8E)-2-((3R)-3-((2R, 3S)-3-(5-cyclopropyl-3H-1,2-dioxol-3-yl)-2-ethyl-3-methylcyclohexylidene) ethylidene)-4-methylenecyclohexane-1,3-diol)**                                                                                                                                                                                                                                                                                 
  Colorectal cancer xenograft                                                                                                                                              i.p., 2 μg/kg every 2 days                                                                                                      8 days                      Inhibition of tumor growth                                                                                        Berkovich et al., [@B8]
  **PRI-2205 ((5E,7E)-22-ene-26,27-dehydro-1 α, 25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                                                 
  Breast and lung cancer xenograft                                                                                                                                         s.c., 10 μg/kg 2 or 3×/week + cytostatics                                                                                       18--21 days                 Combination of analogs with low doses of cytostatics is not effective                                             Wietrzyk et al., [@B103]
  **PRI-1906 ((24E)-(1S)-24-dehydro-24a-homo-1α,25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                                                 
  Inoculation with mice breast cancer cells                                                                                                                                s.c., 0.1 or 1 μg/kg/d                                                                                                          9 or 11 days                No effects                                                                                                        Wietrzyk et al., [@B104]
  **BXL-01-0126 (20R-(4-hydroxy-4-methylpentyl)-23-yne-26,27-hexafluoro-19-nor-1 α, 25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                             
  Acute myeloid leukemia xenograft                                                                                                                                         i.p., 0.0625 μg                                                                                                                 1 injection                 Cathelicidin antimicrobial peptide present in systemic circulation                                                Okamoto et al., [@B73]
  **BXL0124 (20R-21(3-hydroxy-3-deuteromethyl-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-1 α, 25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                               
  Breast cancer xenograft                                                                                                                                                  i.p., 0.1 μg/kg or oral 0.03/0.1 μg/kg 6 days/week                                                                              5 weeks                     Suppressed tumor growth                                                                                           So et al., [@B91]
  Transgenic mice with breast cancer (ErbB2/Her-2/neu overexpressing tumors)                                                                                               i.p., 0.3 μg/kg 3×/week                                                                                                         Approximately 38 weeks      Inhibition of tumor growth and regulation of ErbB2/AKT/ERK pathway                                                Lee et al., [@B53]
  **Gemini0097 (20R-21(3-trideuteromethyl-3-hydroxy-4,4,4-trideuterobutyl)-23-yne-26,27-hexafluoro-19-nor-1 α, 25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                  
  ER-negative breast cancer xenograft                                                                                                                                      i.p., 0.1 μg/kg/d                                                                                                               9 weeks                     Suppressed tumor growth                                                                                           Lee et al., [@B52]
  Chemically-induced breast cancer (ER positive)                                                                                                                           i.p., 0.03/0.1/0.3 μg/kg 5days/week                                                                                             9 weeks                     Inhibition of tumor burden                                                                                        
  **MART-10 (19-nor-2 α-(3-hydroxypropyl)-1 α, 25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                                                  
  Pancreatic cancer xenograft                                                                                                                                              i.p., 0.3 μg/kg 2×/week                                                                                                         3 weeks                     Inhibition of tumor growth                                                                                        Chiang et al., [@B12]
  **1 α,25(OH)**~2~**D**~3~**-3-bromoacetate**                                                                                                                                                                                                                                                                                                                                                                                                           
  Kidney cancer xenograft                                                                                                                                                  i.p., 0.75 μg/kg every third day                                                                                                80 days                     Reduced tumor size and increased apoptosis                                                                        Lambert et al., [@B50]
  **Ro26-2198 (16,23Z-diene-26,27-F6-19-nor-1 α, 25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                                                
  Chemically-induced colorectal cancer                                                                                                                                     0.01 μg/kg/d via mini-osmotic pump                                                                                              28 days                     Inhibition of dysplasia progression and inhibition of proliferation and pro-inflammatory signals                  Fichera et al., [@B25]

For studies preceding 2007 the reader is referred to other reviews (Eelen et al., [@B20]).

Since vitamin D and its analogs do not possess cytostatic properties, many *in vivo* studies have focused on vitamin D analog cancer treatment combined with radiotherapy and/or chemotherapy. When seocalcitol **\[10\]** is combined with radiotherapy in a xenograft model for breast cancer, the anti-cancer effects are more effective compared to monotherapy (Sundaram et al., [@B92]). Another analog, tacalcitol **\[6\]**, has been investigated in colorectal cancer xenograft in combination with different standard chemotherapies. Different concentrations as well as administration routes of tacalcitol **\[6\]** or PRI-2205 (an analog of calcipotriol) **\[18\]** were used in combination with different concentrations of 5-fluorouracil (5-FU). Using specific analog doses and chemotherapy schedules, a synergistic effect on the prolongation of the life span of the mice is achieved (Milczarek et al., [@B65]). Also the combination with irinotecan or oxaliplatin was investigated. In this study the mice also show a longer life span and a stronger tumor growth inhibition compared to monotherapy when certain doses of tacalcitol **\[6\]** and chemotherapy were used. However, some combinations were more toxic than the monotherapies (Milczarek et al., [@B66]). Other studies report better effects when combining calcipotriol **\[7\]** and diclofenac in a non-melanoma skin cancer model (Pommergaard et al., [@B79]). However, the combination of vitamin D analogs with chemotherapy does not always result in additive or synergistic effects. Combining maxacalcitol **\[5\]** and 5-FU did not enhance anti-tumor effects in a chemically induced breast cancer model (Iino et al., [@B39]). Another study investigated calcipotriol **\[7\]** and its derivatives in breast and lung cancer *in vivo* models and concluded that these analogs and low dose cytostatics are not effective in the used models (Wietrzyk et al., [@B103]). Also tacalcitol **\[6\]** in combination with cyclophosphamide does not lead to a significant difference in tumor growth inhibition compared to the vehicle treatment (Wietrzyk et al., [@B104]).

In view of the promising results that certain vitamin D analogs show against cancer *in vitro* and *in vivo* animal models, some analogs have been tested in cancer patients (Table [4](#T4){ref-type="table"}). Seocalcitol **\[10\]** is an analog that has been extensively studied *in vitro* and *in vivo* in different cancer models, however in clinical trials the results are rather disappointing. Patients with advanced breast or colon cancer were treated with different doses of seocalcitol **\[10\]** (most patients tolerate 7 μg/d) but none of them showed a complete or partial response (Gulliford et al., [@B32]). Also oral seocalcitol **\[10\]** treatment in patients with inoperable pancreatic cancer exhibited no objective anti-tumor activity (Evans et al., [@B24]). Two out of 33 patients with inoperable hepatocellular carcinoma showed a complete response after oral seocalcitol **\[10\]** treatment, however the majority of the patients presented stable or progressive disease (Dalhoff et al., [@B16]). Inecalcitol **\[14\]** is in an early stage II of its clinical trial in chronic lymphocytic leukemia. Fifteen patients received 2 mg/d orally and one patient had a 90% decrease in blood lymphocyte count after 10 months of treatment, in 8 other patients blood lymphocyte count stopped growing when the treatment started (Hybrigenics, [@B38]). Intravenous administration of paricalcitol **\[2\]**, an analog that is approved for secondary hyperparathyroidism, also displayed no objective responses in patients with androgen-independent prostate cancer. However, elevated serum PTH levels, which are common for advanced prostate cancers, are reduced by the analog (Schwartz et al., [@B85]). Doxercalciferol **\[3\]**, also used in the treatment against secondary hyperparathyroidism, was investigated in androgen-independent prostate cancer patients. A phase I study administered oral doxercalciferol **\[3\]** between 5 and 15 μg/d, which was well tolerated by the patients (Liu et al., [@B56]). In the following phase II study, patients were treated with 12.5 μg/d for a minimum of 8 weeks and 30% of these patients experienced stable disease for over 6 months (Liu et al., [@B57]). Oral treatment of non-Hodgkin\'s lymphoma patients with 1 μg/d alfacalcidol **\[8\]**, a pre-metabolite of 1,25(OH)~2~D~3~, resulted in a low overall response. Out of 34 treated patients, only 4 had a complete response and 4 others showed a partial response to the treatment (Raina et al., [@B82]). Calcipotriol **\[7\]** is often used to treat skin psoriasis and has thus been investigated in patients with locally advanced or cutaneous metastases from breast cancer. In both studies the analog was applied topically at a dose of 100 μg/d. One study reported no response after 3 months of treatment (O\'Brien et al., [@B71]), while in the other study 3 patients showed a 50% reduction in the diameter of treated lesions after 6 weeks (Bower et al., [@B11]). A more recently developed analog, ILX23-7553 **\[19\]**, was investigated in 16 patients with advanced solid tumors but no objective response was seen (Jain et al., [@B42]). Similar to the *in vivo* studies, clinical trials have also combined vitamin D analogs with standard radiotherapy or chemotherapy. Metastatic breast cancer patients were given oral paricalcitol **\[2\]** doses between 2 and 7 μg/d in combination with taxane-based chemotherapy and this regimen was well tolerated by the patients (Lawrence et al., [@B51]). Oral inecalcitol **\[14\]** was given to patients with hormone-refractory prostate cancer in combination with docetaxel for maximum 18 weeks. This study had a response rate of 85% based on a PSA decline of at least 30% within 3 months of treatment (Hybrigenics, [@B38]). In a small study with acute non-lymphoid leukemia patients the combination of alfacalcidol **\[8\]** and chemotherapy resulted in 17% of the patients with a complete response and 45% with a partial response (Petrini et al., [@B78]). The same analog was combined with standard treatment of surgery, radiotherapy, and/or chemotherapy in glioblastoma and anaplastic astrocytomas. Here, 0.04 μg/kg/d alfacalcidol **\[8\]** was administered resulting in 27% of the patients with progressive regression of the lesion and complete clinical remission (Trouillas et al., [@B95]). In metastatic renal cell carcinoma patients, oral treatment of 1 μg alfacalcidol/d **\[8\]** was combined with a 3 weekly administration of interferon-α for minimal 3 months. In these patients 25% had a partial response to the combination therapy (Obara et al., [@B70]). Randomized, placebo-controlled studies have been conducted with oral doxercalciferol **\[3\]** or alfacalcidol **\[8\]**. One study administered 10 μg/d doxercalciferol **\[3\]** or placebo during 4 weeks to patients with localized prostate cancer or high-grade prostatic intraepithelial neoplasia. However, no beneficial effects in serum or tissue markers were seen (Gee et al., [@B27]). Another study used the same dose in metastatic androgen-independent prostate cancer patients but combined the treatment with docetaxel. Also here, no enhanced PSA response rate or survival rate was seen after 4 weeks of treatment (Attia et al., [@B5]). Oral alfacalcidol **\[8\]** or placebo was given to patients with myelodysplastic syndromes. In the patients treated with the analog, a prolongation of leukemic transformation-free survival was seen compared to the placebo group (Motomura et al., [@B67]). Despite the promising *in vitro* and *in vivo* results of vitamin D analogs in cancer models, clinical trials have failed to proof the effects of vitamin D analogs in cancer patients. Vitamin D and its analogs lack cytotoxic activity, so using these analogs in combination with standard therapies such as radio- and chemotherapy is probably more effective than using the analogs as monotherapy. Next to the combination of analogs with standard cancer therapies, it is also possible that these analogs need to be given for a longer period of time or that treatment with analogs has to be started earlier, for example in early stages of disease or even as chemoprevention.

###### 

**Clinical trials with vitamin D analog supplementation**.

  **Cancer type**                                                                **Sample size**   **Dosage vitamin D analog**                                                                   **Duration of treatment**   **Outcome**                                                                                                                                                                                              **References**
  ------------------------------------------------------------------------------ ----------------- --------------------------------------------------------------------------------------------- --------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------
  **Seocalcitol (22,24-diene-24,26,27-trishomo-1 α, 25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                          
  Inoperable hepatocellular carcinoma                                            33                Oral individual dosage, most patients tolerate 10 μg/d                                        Up to 1 year                2 patients with complete response; 12 with stable disease; 19 with progressive disease                                                                                                                   Dalhoff et al., [@B16] (uncontrolled trial)
  Inoperable pancreatic cancer                                                   36                Oral individual dosage, most patients tolerate 10--15 μg/d                                    Minimum 8 weeks             No objective anti-tumor activity                                                                                                                                                                         Evans et al., [@B24] (uncontrolled trial)
  Advanced breast cancer and colorectal cancer                                   36                Individual dosage (solution), most patients tolerate 7 μg/d                                   From 5 days up to 1 year    No complete or partial responses                                                                                                                                                                         Gulliford et al., [@B32] (uncontrolled trial)
  **Inecalcitol (19-nor-14-epi-23-yne-1 α, 25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                                   
  Hormone-refractory prostate cancer                                             54                Oral individual dosage, maximum tolerated dose is 4 mg/d + docetaxel (chemotherapy)           Maximum 18 weeks            85% response rate based on a PSA decline of at least 30% within 3 months                                                                                                                                 Hybrigenics, [@B38] (uncontrolled trial)
  Chronic lymphocytic leukemia                                                   15                Oral 2 mg/d                                                                                   Not found                   1 patient had a 90% decrease in blood lymphocyte count after 10 months of treatment; in 8 patients blood lymphocyte count stopped increasing when treatment was started; 6 patients showed no response   Hybrigenics, [@B38] (uncontrolled trial)
  **Paricalcitol (19-nor-1 α,25(OH)**~2~**D**~2~**)**                                                                                                                                                                                                                                                                                                                                                                                 
  Metastatic breast cancer                                                       24                Oral individual dosage, 2--7 μg/d + taxane-based chemotherapy                                 8 weeks                     Well tolerated regimen                                                                                                                                                                                   Lawrence et al., [@B51] (uncontrolled)
  Androgen-independent prostate cancer                                           18                i.v., Individual dosage, 3×/week 5--25 μg                                                     Up to 12 weeks              No objective response, reduced serum PTH levels                                                                                                                                                          Schwartz et al., [@B85] (uncontrolled)
  **Doxercalciferol (1 α (OH)D**~2~**)**                                                                                                                                                                                                                                                                                                                                                                                              
  Localized prostate cancer and high grade prostatic intraepithelial neoplasia   31                Oral, 10 μg/d                                                                                 4 weeks                     No beneficial effects in serum and tissue markers                                                                                                                                                        Gee et al., [@B27] (placebo-controlled)
  Metastatic androgen-independent prostate cancer                                70                Oral, 10 μg/d + docetaxel                                                                     4 weeks                     No enhanced PSA response rate or survival                                                                                                                                                                Attia et al., [@B5] (placebo-controlled)
  Advanced androgen-independent prostate cancer                                  26                Oral, 12.5 μg/d                                                                               Minimum 8 weeks             30% experienced stable disease for over 6 months                                                                                                                                                         Liu et al., [@B57] (uncontrolled)
  Advanced androgen-independent prostate cancer                                  25                Oral individual dosage, 5--15 μg/d                                                            Minimum 8 weeks             Well tolerated, maximal tolerated dose was not reached                                                                                                                                                   Liu et al., [@B56] (uncontrolled)
  **Alfacalcidol (1 α (OH)D~3~**)                                                                                                                                                                                                                                                                                                                                                                                                     
  Metastatic renal cell carcinoma                                                16                Oral, 1 μg/d + interferon-α (3×/week)                                                         Minimum 3 months            25% had partial response                                                                                                                                                                                 Obara et al., [@B70] (uncontrolled)
  Glioblastoma and anaplastic astrocytomas                                       11                0.04 μg/kg/d + surgery/chemotherapy/ radiotherapy                                             Not found                   27% showed progressive regression of the lesion and had a complete clinical remission                                                                                                                    Trouillas et al., [@B95] (uncontrolled)
  Myelodysplastic syndromes                                                      30                Oral, 4--6 μg/d                                                                               Median 17 months            Prolongation of leukemic transformation-free survival                                                                                                                                                    Motomura et al., [@B67] (placebo-controlled)
  Acute non-lymphoid leukemia                                                    11                Analog + chemotherapy                                                                         Not found                   17% complete remission, 45% partial remission                                                                                                                                                            Petrini et al., [@B78] (uncontrolled)
  Progressive low-grade non-Hodgkin\'s lymphoma                                  34                Oral, 1 μg/d                                                                                  Minimum 8 weeks             4 patients has a complete response, 4 other patients had a partial response                                                                                                                              Raina et al., [@B82] (uncontrolled)
  **Calcipotriol (22-ene-26,27-dehydro-1 α, 25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                                  
  Locally advanced or cutaneous metastatic breast cancer                         19                Topical 100 μg/d                                                                              6 weeks                     3 patients showed 50% reduction in diameter of treated lesions                                                                                                                                           Bower et al., [@B11] (uncontrolled)
  Locally advanced or cutaneous metastatic breast cancer                         15                Topical 100 μg/d                                                                              3 months                    No response                                                                                                                                                                                              O\'Brien et al., [@B71] (uncontrolled)
  **ILX23-7553 (16-ene-23-yne-1 α, 25(OH)**~2~**D**~3~**)**                                                                                                                                                                                                                                                                                                                                                                           
  Advanced solid tumors                                                          16                Oral individual dosage, 1.7--37.3 μg/m^2^/d for 3 consecutive days, repeated in 7-day cycle   Minimum 3 weeks             No objective response                                                                                                                                                                                    Jain et al., [@B42] (uncontrolled)

Conclusions and perspectives
============================

Vitamin D and its analogs exhibit strong antiproliferative and prodifferentiating effects on different normal and malignant cell types. Several vitamin D analogs have been approved for treating psoriasis, osteoporosis, and secondary hyperparathyroidism and are often used as first or second-line treatment option. Despite promising *in vitro* as well as *in vivo* results in various cancer models, vitamin D analog treatment in clinical trials with cancer patients failed to prove efficacy in most trials. Different combinations of analogs and standard cancer therapies should be further explored as well as the correct duration and timing of administration. To unravel the exact working mechanisms of vitamin D analogs more research studies should compare the effects of vitamin D analogs in different cell types to the mother compound. Furthermore, differences between 1,25(OH)~2~D~3~ and its analogs are probably more due to their differences in metabolism and coactivator recruitment than from different genetic regulations. However, some fields such as epigenetics and proteomics remain largely unexplored in comparing the potentially distinctive effects of 1,25(OH)~2~D~3~ and its analogs. Since all current genomic and transcriptomic studies focus on established human cell lines, micro-array, and ChIP techniques comparing the effects of 1,25(OH)~2~D~3~ and its analogs on human primary tumor tissues should be investigated in the future.
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